Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment

被引:2
|
作者
Li, Jun [1 ]
Dong, Xiao-Qin [2 ]
Cao, Li-Hua [3 ]
Zhang, Zhan-Qing [4 ]
Zhao, Wei-Feng [5 ]
Shang, Qing-Hua [6 ]
Zhang, Da-Zhi [7 ]
Ma, An-Lin [8 ]
Xie, Qing [9 ]
Gui, Hong-Lian [9 ]
Zhang, Guo [10 ]
Liu, Ying-Xia [11 ]
Shang, Jia [12 ]
Xie, Shi-Bin [13 ]
Liu, Yi-Qi [1 ]
Zhang, Chi [1 ]
Wang, Gui-Qiang [1 ,14 ,15 ]
Zhao, Hong [1 ,15 ]
机构
[1] Peking Univ First Hosp, Ctr Liver Dis, Dept Infect Dis, Beijing, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept & Inst Infect Dis, Wuhan, Hubei, Peoples R China
[3] Third Hosp Qinhuangdao, Dept Hepatol, Qinhuangdao, Peoples R China
[4] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, Shanghai, Peoples R China
[5] Xinxiang Med Univ, Affiliated Hosp 3, Dept Infect Dis, Xinxiang, Peoples R China
[6] 88 Hosp Chinese Peoples Liberat Army PLA, Dept Hepatol, Jinan, Peoples R China
[7] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing, Peoples R China
[8] China Japan Friendship Hosp, Dept Infect Dis, Beijing, Peoples R China
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Infect Dis, Shanghai, Peoples R China
[10] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Gastroenterol, Nanning, Peoples R China
[11] Third Peoples Hosp Shenzhen, Dept Infect Dis, Shenzhen, Peoples R China
[12] Peoples Hosp Henan, Dept Infect Dis, Zhengzhou, Peoples R China
[13] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou, Peoples R China
[14] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China
[15] Peking Univ Int Hosp, Dept Hepatol, Beijing, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2023年 / 13卷
关键词
chronic hepatitis B; persistant viremia; HBV DNA; anti-hepatitis B virus core antibody; fibrosis; carcinoma; TENOFOVIR DISOPROXIL FUMARATE; SIMPLE NONINVASIVE INDEX; HEPATOCELLULAR-CARCINOMA; ALANINE AMINOTRANSFERASE; VIROLOGICAL RESPONSE; SIGNIFICANT FIBROSIS; VIRAL SUPPRESSION; NAIVE PATIENTS; CORE ANTIBODY; RISK;
D O I
10.3389/fcimb.2023.1151899
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionThe clinical significance of persistent positive in Hepatitis B Virus (HBV) DNA level in patients receiving antiviral therapy is not well known. We investigated factors associated with persistent viremia (PV) in patients with chronic hepatitis B (CHB) given 78-week entecavir. MethodsA total of 394 treatment-naive CHB patients who had undergone liver biopsy at baseline and week 78 of treatment were analyzed in this prospective multicentre study. We identified patients with PV (above the lower limit of quantification, 20 IU/ml) after 78 weeks of entecavir therapy. Stepwise, forward, multivariate regression analyses of specified baseline parameters were apllied to identify factors associated with PV. Futhermore, we assessed the incidence of hepatocellular carcinoma (HCC) in all patients using models of the risk of HCC development. ResultsOf the 394 patients, 90 (22.8%) still with PV after 78-week antiviral treatment. Factors associated significantly with PV (vs complete virological response, CVR) were HBV DNA level & GE;8 log10 IU/mL (OR, 3.727; 95% CI, 1.851-7.505; P < 0.001), Anti-HBc level < 3 log10 IU/mL (OR, 2.384; 95% CI, 1.223-4.645; P=0.011), and HBeAg seropositivity (OR, 2.871; 95% CI, 1.563-5.272; P < 0.001). Patients with PV were less likely to have fibrosis progression and HCC development than those with the CVR. Of the 11 HBeAg-positive patients with HBV DNA level & GE;8 log10 IU/mL and Anti-HBc level < 3 log10 IU/mL at baseline, 9 (81.8%) had persistent positivity in HBV DNA level and 0 had fibrosis progression at week 78 of treatment. DiscussionIn conclusion, HBV DNA level & GE;8 log10 IU/mL, Anti-HBc level < 3 log10 IU/mL and HBeAg seropositivity at baseline contribute to PV in patients with CHB receiving 78-week antiviral treatment. In addition, the rate of fibrosis progression and the risk of HCC development in patients with PV were kept low. The complete protocol for the clinical trial has been registered at clinicaltrials.gov (NCT01962155 and NCT03568578).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
    Peng, Cheng-Yuan
    Hsieh, Tsung-Cheng
    Hsieh, Tsai-Yuan
    Tseng, Kuo-Chih
    Lin, Chih-Lin
    Su, Tung-Hung
    Tseng, Tai-Chung
    Lin, Hans Hsienhong
    Wang, Chia-Chi
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (04) : 308 - 313
  • [2] On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy
    Huang, Yi-Jie
    Chang, Chi-Sen
    Peng, Yen-Chun
    Yeh, Hong-Zen
    Yang, Sheng-Shun
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2017, 80 (06) : 341 - 346
  • [3] Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment
    Li, Zhong-Bin
    Chen, Dan-Dan
    Jia, Yun-Fei
    He, Qing-Juan
    Cui, Li
    Du, Feng-Xia
    Kang, Yao-Jie
    Feng, Xin
    He, Mengwen
    Jin, Xue-Yuan
    Chen, Jing
    Wang, Yudong
    Ji, Dong
    Lau, George
    Wu, Shu-Gao
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [4] Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA
    Shi, Hong
    Huang, Mingxing
    Lin, Guoli
    Li, Xiangyong
    Wu, Yuankai
    Jie, Yusheng
    Chong, Yutian
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [5] Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
    Wong, Grace Lai-Hung
    Chan, Henry Lik-Yuen
    Chan, Hoi-Yun
    Tse, Pete Chi-Hang
    Tse, Yee-Kit
    Mak, Christy Wing-Hin
    Lee, Stanley King-Yeung
    Ip, Zoe Man-Yi
    Lam, Andrew Ting-Ho
    Iu, Henry Wing-Hang
    Leung, Joyce May-Sum
    Wong, Vincent Wai-Sun
    GASTROENTEROLOGY, 2013, 144 (05) : 933 - 944
  • [6] Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy
    Jacobson, Ira M.
    Washington, Mary K.
    Buti, Maria
    Thompson, Alexander
    Afdhal, Nezam
    Flisiak, Robert
    Akarca, Ulus Salih
    Tchernev, Konstantin G.
    Flaherty, John F.
    Schall, Raul Aguilar
    Myers, Robert P.
    Subramanian, G. Mani
    McHutchison, John G.
    Younossi, Zobair
    Marcellin, Patrick
    Patel, Keyur
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (07) : 1087 - +
  • [7] LOW-LEVEL VIREMIA IN CHRONIC HEPATITIS B PATIENTS RECEIVING TENOFOVIR OR ENTECAVIR
    Adilijiang, Munire
    Zhang, Yongping
    HEPATOLOGY, 2022, 76 : S243 - S244
  • [8] HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B
    M. Pawłowska
    W. Halota
    E. Smukalska
    T. Woźniakowska-Gęsicka
    J. Kupś
    European Journal of Clinical Microbiology & Infectious Diseases, 2012, 31 : 571 - 574
  • [9] HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B
    Pawlowska, M.
    Halota, W.
    Smukalska, E.
    Wozniakowska-Gesicka, T.
    Kups, J.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (04) : 571 - 574
  • [10] The Effect of HBV DNA level on The Development of Hepatocelluar Carcinoma in Patients with Hepatitis B Virus-associated Liver Cirrhosis during Entecavir Treatment
    Kwon, Oh Sang
    Park, Hyeonsu
    Lee, Jong Joon
    Jung, Young Kul
    Choi, Duck Joo
    Kim, Yun Soo
    Kim, Ju Hyun
    HEPATOLOGY, 2013, 58 : 1253A - 1253A